GlaxoSmithKline (LON:GSK) Stock Rating Reaffirmed by Credit Suisse Group

Credit Suisse Group reissued their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a report published on Monday, November 12th.

Several other brokerages also recently issued reports on GSK. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline in a research note on Tuesday, August 21st. Berenberg Bank reaffirmed a buy rating and set a GBX 1,790 ($23.39) price target on shares of GlaxoSmithKline in a research note on Thursday, August 23rd. Liberum Capital downgraded shares of GlaxoSmithKline from a buy rating to a hold rating and lifted their price target for the company from GBX 1,630 ($21.30) to GBX 1,700 ($22.21) in a research note on Thursday, August 30th. Jefferies Financial Group set a GBX 1,775 ($23.19) price target on shares of GlaxoSmithKline and gave the company a buy rating in a research note on Thursday, August 16th. Finally, Barclays reaffirmed an overweight rating on shares of GlaxoSmithKline in a research note on Friday, August 10th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of GBX 1,512.99 ($19.77).

LON GSK traded up GBX 19.40 ($0.25) during trading on Monday, hitting GBX 1,437.40 ($18.78). The stock had a trading volume of 13,007,869 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a one year low of GBX 1,235.20 ($16.14) and a one year high of GBX 1,724.50 ($22.53).

The company also recently declared a dividend, which will be paid on Thursday, January 10th. Shareholders of record on Thursday, November 15th will be issued a GBX 19 ($0.25) dividend. This represents a yield of 1.26%. The ex-dividend date of this dividend is Thursday, November 15th.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: How to calculate the annual rate of depreciation

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply